StockData
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. (EWTX) stock

EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$42.04−1.64 (-3.75%)

Close on Nov 17, 2026Market cap $4.57BP/E –Yield –

Edgewise Therapeutics cash

Cash and short-term investments held at the end of each period.

Edgewise Therapeutics's cash was $72.32M at Jun 30, 2026. For fiscal 2025 it was $61.15M, up 46.8% from the year before. The highest annual figure on record is $104.92M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$61.15M+46.8%
FY2024Dec 31, 2024$41.67M-51.6%
FY2023Dec 31, 2023$86.10M+291.5%
FY2022Dec 31, 2022$21.99M+41.3%
FY2021Dec 31, 2021$15.57M-85.2%
FY2020Dec 31, 2020$104.92M+343.6%
FY2019Dec 31, 2019$23.65M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$72.32M+66.6%
Q1 FY2026Mar 31, 2026$33.21M-33.5%
Q4 FY2025Dec 31, 2025$61.15M+46.8%
Q3 FY2025Sep 30, 2025$46.00M+2.7%
Q2 FY2025Jun 30, 2025$43.40M-0.2%
Q1 FY2025Mar 31, 2025$49.92M+65.0%
Q4 FY2024Dec 31, 2024$41.67M-51.6%
Q3 FY2024Sep 30, 2024$44.81M+36.0%
Q2 FY2024Jun 30, 2024$43.49M+36.7%
Q1 FY2024Mar 31, 2024$30.26M-37.3%
Q4 FY2023Dec 31, 2023$86.10M+291.5%
Q3 FY2023Sep 30, 2023$32.96M-70.0%
Q2 FY2023Jun 30, 2023$31.81M+73.4%
Q1 FY2023Mar 31, 2023$48.23M+40.0%
Q4 FY2022Dec 31, 2022$21.99M+41.3%
Q3 FY2022Sep 30, 2022$109.75M+938.2%
Q2 FY2022Jun 30, 2022$18.34M-63.6%
Q1 FY2022Mar 31, 2022$34.45M-84.4%
Q4 FY2021Dec 31, 2021$15.57M-85.2%
Q3 FY2021Sep 30, 2021$10.57M-72.7%
Q2 FY2021Jun 30, 2021$50.40M+198.8%
Q1 FY2021Mar 31, 2021$221.04M+957.3%
Q4 FY2020Dec 31, 2020$104.92M+343.6%
Q3 FY2020Sep 30, 2020$38.73M–
Q2 FY2020Jun 30, 2020$16.87M–
Q1 FY2020Mar 31, 2020$20.91M–
Q4 FY2019Dec 31, 2019$23.65M–

More Edgewise Therapeutics figures

See a number that looks wrong?